Advertisement


Michael Soike, MD, on Brain Metastases: Radiosurgery vs Radiotherapy

2018 ASTRO Annual Meeting

Advertisement

Michael Soike, MD, of Wake Forest University Medical Center, discusses results from a large multicenter study that suggests salvage stereotactic radiosurgery leads to improved overall survival compared with whole-brain radiotherapy for patients with progressive brain metastases (Presentation 296 in Scientific Symposium 40).



Related Videos

Solid Tumors

David Palma, MD, PhD, on Oligometastatic Tumors: Results From the SABR-COMET Trial

David Palma, MD, PhD, of the London Health Sciences Centre, discusses study findings on improvement in survival following stereotactic ablative radiation for oligometastatic tumors (Presentation 5 in PL 01).

Prostate Cancer

Alan Pollack, MD, on Prostate Cancer: Results From the SPPORT Trial

Alan Pollack, MD, of the University of Miami, discusses study findings on short-term androgen-deprivation therapy with or without pelvic lymph node treatment added to prostate bed–only salvage radiotherapy (Abstract LBA5).

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer: Prospective Trials Update

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses a session on data from several long-term studies on localized disease, including optimal sequencing of radiation and androgen-deprivation therapy; the efficacy and toxicity of SBRT; conventional vs hypofractionated radiation therapy; and dose escalation (Scientific Symposium 08).

Issues in Oncology

Vinai Gondi, MD, on Treating Brain Metastases, Preserving Cognitive Function

Vinai Gondi, MD, of Northwestern Medicine, discusses the early results of a phase III NRG Oncology trial that suggests a practice change in treating brain metastases: avoiding the hippocampus when delivering whole-brain radiotherapy (Abstract LBA9).

Lung Cancer

Daniel R. Gomez, MD, on NSCLC: Findings From a Phase II Treatment Trial

Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall survival compared with maintenance therapy and observation in oligometastatic non–small cell lung cancer (Abstract LBA3).

Advertisement

Advertisement




Advertisement